Mode
Text Size
Log in / Sign up
N/A N=44 Randomized Treatment

Effectiveness and Safety of a Water-based and a Silicone-based Personal Lubricants With Sensory Action

Dyspareunia · Vaginal Dryness

Enrolled (actual)
44
Serious AEs
0.6%
Results posted
Feb 2025
Primary outcome: Primary: Female Sexual Function Index (FSFI) Score Compared to Baseline — 4.14; 5.95 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Lubricant A (sensate water-based personal lubricant) and Comparator A (non-sensate water-based lubricant) (Device); Lubricant B (sensate silicone-based personal lubricant) and Comparator B (non-sensate silicone-based personal lubricant) (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Reckitt Benckiser Healthcare (UK) Limited
Primary completion
May 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Female Sexual Function Index (FSFI) Score Compared to Baseline
4.14; 5.95
SECONDARY
Change From Baseline in the Female Sexual Function Index (FSFI) Individual Domain Scores
0.27; 0.17; 0.25; 0.62; 1.00; 1.39
SECONDARY
Subject Perception of the Personal Lubricants Through Subject Perceived Questions
32; 30; 1; 2; 0; 0
SECONDARY
The Evaluation of Product Effectiveness, Tolerability and Usability (Subjective Opinion)
12; 17; 14; 11; 5; 1
SECONDARY
The Impression of Change in the Sexual Intimacy (Subjective Opinion)
1.27; 1.34
SECONDARY
The Assessment of the Vaginal Epithelial Tolerability (VET)
0; 3; 0; 1; 1; 1
SECONDARY
Tolerability as Assessed by Subject Perceived Questions
9; 8; 1; 1; 2; 0
SECONDARY
The Assessment of Overall Tolerance for Each Participant
7; 5; 5; 4; 0; 0
SECONDARY
The Assessment of Oral Mucosal Tolerance
0; 0; 0; 0; 0; 0
SECONDARY
Overall Proportion of Participants With Adverse Events/Adverse Device Effects (AEs/ADEs)
10; 13; 0; 0

Summary

This clinical investigation will look at the effectiveness and safety of two personal lubricants for the relief of intimate discomfort associated with vaginal dryness.

Eligibility Criteria

Inclusion Criteria

  • Subject has provided written informed consent.
  • Subject is aged at least 18 years.
  • Subject in a mutually monogamous heterosexual relationship (≥3 months) who is sexually active, defined as having sexual intercourse at least once a week.
  • Female subject that agrees to have a gynaecological pelvic examination to ensure no significant disease findings and have intact skin and mucous in the test region assessed by the gynaecologist at all the relevant time points.
  • Female subject that agrees to an oral exam by a dermatologist to ensure no significant disease findings and have intact skin and mucous in the test region.
  • Subjects reporting mild to moderate vaginal dryness and dyspareunia during sex (when not using lubricant) in the past 3 months as confirmed on the Verbal Rating Scale (VRS).
  • Pre-menopausal Inclusion Criteria: Female subject of childbearing potential who is willing to use a highly effective method of contraception throughout the clinical investigation.
  • Post-menopausal Inclusion Criteria: Female subject in post-menopausal phase defined as having amenorrhea (absence of menstruation) for at least 12 months.
  • Post-menopausal Inclusion Criteria: Female subject with premature menopause - surgical menopause or physiological menopause within the last 12 months or after having received chemotherapy.

Exclusion Criteria

  • Subject who has previously experienced an irritant or allergic reaction to any personal lubricant, vaginal moisturiser or female hygiene product or known to have any contact allergen or allergy/hypersensitivity to the test product ingredients.
  • Female subject with history of mucosal intolerance to warming agents.
  • Female subject with continuous or intermittent oral allergy syndrome or burning mouth syndrome of history of thereof.
  • Female subject with urinary, vaginal infection (fungal, bacterial) or sexually transmitted infection which may affect the study outcomes or the safety of the subject.
  • Female subject that has any condition of the oral cavity as determined by the investigator.
  • Male subject has broken skin or wounds in the intimate area.
  • Female subject with a history of skin disorder, which in the opinion of the investigation will affect study outcome.
  • Female subject with autoimmune conditions or any medical conditions which in the opinion of the investigator could compromise the immune function.
  • Female subject who has used any kind of topical histamine and/or topical hormonal based product in the form of an intravaginal cream or moisturiser for local treatment of vaginal dryness in the past 3 months.
  • Female subject using non-medicated, over the counter product, herbal/natural remedies on the vulva, vaginal opening and inside the vagina and is unwilling to stop at least 7 days prior to screening and throughout the duration of clinical investigation.
  • Female subject showing vaginal prolapse and/or other medical conditions that could interfere with the investigation conduct and participation.
  • Female subject who has had surgical cervical excision or vaginal and/or vulvar procedures, including laser and cosmetic procedures to the vulva or vagina in the previous year.
  • Pre-menopausal Exclusion Criteria: Female subject who is pregnant (as confirmed by a positive pregnancy test), breast-feeding or trying to conceive.
  • Post-Menopausal Exclusion Criteria: Female subject that has had previous episodes of vaginal bleeding of unknown origin within the last 6 months.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05644444). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search